Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Another genetic treatment for sickle cell ... Vertex Pharmaceuticals and Crispr Therapeutics, which developed Casgevy, have not publicly said how many patients have received the therapy so ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

Researchers have identified a molecular mechanism driving the structural abnormalities leading to lissencephaly that have ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA. Ben Hargreaves provides an overview of the treatment ...

received a significant boost with the approval of a CRISPR-based therapy, Casgevy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia in patients aged 12 ...